Drug Trial Radar · NCT06342921
ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection
Last checked: Nov 19, 2026Latest source record: Jan 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
749
Actual
Start
Dec 7, 2022
Primary completion
Oct 8, 2023
Study completion Jan 22, 2024
Sponsor
- Lead sponsor
- Jiaxing AnDiCon Biotech Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection. The main aim to answer: * Phase II study is to evaluate the efficacy of ADC189 tablets in the treatment of adult influenza subjects and determine the optimal therapeutic dose by analyzing the time of virus titer turning to negative. All the results will be used to design the Phase III study. * Phase III study is to evaluate the efficacy of ADC189 tablets by analyzing the duration of remission of all influenza symptoms in adolescents and adults subjects with influenza. Participants will be taken ADC189 teblets/Placebo once, and be observed by 22 days. Phase II study has 3 groups: 15 mg ADC189; 45 mg ADC189; and Placebo; Phase III study has 2 groups: 45 mg ADC189; and Placebo.
Conditions
- Safety Issues
- Effect of Drug
Interventions
15 mg ADC189Drug
Use only once during the whole study.
45 mg ADC189Drug
Use only once during the whole study.
PlaceboDrug
Use only once during the whole study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the severity of influenzaTime frame: 22 days
- the safety of study drugTime frame: 22 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rui Jin Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.